Alto Neurosciences is a biopharma company that uses biomarkers of the brain to understand prospective drug therapies for psychiatric care of patients. Alto Neurosciences specializes in precision medicine, and has established a pipeline of treatments for various mental health conditions such as post-traumatic stress disorders (PTSD) and depression.

Register for Details

For more details on financing and valuation for Alto Neuroscience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Alto Neuroscience

Forge green plus iconForge green minus icon

What is Alto Neuroscience's funding to date?

Alto Neuroscience has raised $151.37MM to date.
Forge green plus iconForge green minus icon

When was Alto Neuroscience founded?

Alto Neuroscience was founded in 2019.

Who are Alto Neuroscience's major investors?

Valor Equity Partners
Gaingels
Vine Ventures
Point72 Ventures
What If Ventures
Novartis
NJF Capital
National Institutes of Health
Windham Venture Partners
Sobrato Capital
Korify Capitals
Alpha Wave Global
re.Mind Capital
Able Partners
Bioverge Ventures
K2 HealthVentures
InVivium Capital
Lightswitch Capital
Catena Capital
Presight Capital

Alto Neuroscience Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
11/21/2023 Series C $50.31MM raised $XXX.XX $XXX.XX
1/30/2023 Series B $59.26MM raised $XXX.XX $XXX.XX
10/14/2021 Series A $34.08MM raised $XXX.XX $XXX.XX
9/30/2019 Series Seed $7.72MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Nov 15, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.